Biohit Oyj - Total number of voting rights and capital

Biohit Oyj B-shares Subscribed with Stock Options II 201

Biohit Oyj Stock Exchange Release June 18, 2015 at 9:30 a.m. local time (EEST)

A total number of 95,000 new Biohit Oyj B-shares have been subscribed for with
stock options II 2013 during May 5th, 2015 and April 23rd, 2015. These shares
will be entered into the trade register on June 18th, 2015, as of which date
the new shares will establish equal shareholder rights with the company's
existing B-shares. Public trading is expected to begin on NASDAQ OMX Helsinki
as of June 22, 2015 together with the existing B-shares. 

The share subscription price was EUR 2.2766 per share respectively. The entire
subscription price of EUR 216.277 will be credited to the reserve for invested
non-restricted equity, and the company share capital remains unchanged. The
shares have no nominal value. 

After the subscription the number of all Biohit Oyj's shares will rise into
14.315.593 shares (14.220.593) and B-shares will rise into 11.340.093 shares
(11.245.093). The new shares will correspond to a percentage of 0.66% of Biohit
Oyj's total number of shares and 0.13% of the voting rights after registration. 

The share subscription period with stock options II 2013 began on July 1, 2013
and will end June 30, 2015. This subscription is the last subscription of the
II 2013 option series. The option schemes are based on the Biohit Oyj board
resolution of June 19, 2013 and the Annual General Meeting authorization of
April 14, 2014. The terms and conditions of the option schemes with additional
information are available on Biohit Oyj website at www.biohithealthcare.com. 



Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com